Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Macaya, Douoguih"'
Autor:
Julie A. Ake, Kristopher Paolino, Jack N. Hutter, Susan Biggs Cicatelli, Leigh Anne Eller, Michael A. Eller, Margaret C. Costanzo, Dominic Paquin-Proulx, Merlin L. Robb, Chi L. Tran, Lalaine Anova, Linda L. Jagodzinski, Lucy A. Ward, Nicole Kilgore, Janice Rusnak, Callie Bounds, Christopher S. Badorrek, Jay W. Hooper, Steven A. Kwilas, Ine Ilsbroux, Dickson Nkafu Anumendem, Auguste Gaddah, Georgi Shukarev, Viki Bockstal, Kerstin Luhn, Macaya Douoguih, Cynthia Robinson
Publikováno v:
Vaccines, Vol 12, Iss 5, p 497 (2024)
The safety and immunogenicity of the two-dose Ebola vaccine regimen MVA-BN-Filo, Ad26.ZEBOV, 14 days apart, was evaluated in people without HIV (PWOH) and living with HIV (PLWH). In this observer-blind, placebo-controlled, phase 2 trial, healthy adul
Externí odkaz:
https://doaj.org/article/d508ae26d5664c20827179054ade0b7e
Autor:
Adeep Puri, Andrew J. Pollard, Catherine Schmidt-Mutter, Fabrice Lainé, George PrayGod, Hannah Kibuuka, Houreratou Barry, Jean-François Nicolas, Jean-Daniel Lelièvre, Sodiomon Bienvenu Sirima, Beatrice Kamala, Daniela Manno, Deborah Watson-Jones, Auguste Gaddah, Babajide Keshinro, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Publikováno v:
Vaccines, Vol 12, Iss 2, p 210 (2024)
In this prospective, observational study (ClinicalTrials.gov Identifier: NCT02661464), long-term safety information was collected from participants previously exposed to the Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo while enrolled in phase 1, 2, o
Externí odkaz:
https://doaj.org/article/be0eda68b7b14bcebefc7094a6d47a12
Autor:
Daniela Manno, Philip Ayieko, David Ishola, Muhammed O. Afolabi, Baimba Rogers, Frank Baiden, Alimamy Serry-Bangura, Osman M. Bah, Brian Köhn, Ibrahim Swaray, Kwabena Owusu-Kyei, Godfrey T. Otieno, Dickens Kowuor, Daniel Tindanbil, Elizabeth Smout, Cynthia Robinson, Babajide Keshinro, Julie Foster, Katherine Gallagher, Brett Lowe, Macaya Douoguih, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones
Publikováno v:
Emerging Infectious Diseases, Vol 28, Iss 3, Pp 734-738 (2022)
We explored the association of Ebola virus antibody seropositivity and concentration with potential risk factors for infection. Among 1,282 adults and children from a community affected by the 2014–2016 Ebola outbreak in Sierra Leone, 8% were serop
Externí odkaz:
https://doaj.org/article/2254071766d6435e89e08cf0d179f013
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 2, Pp 266-270 (2017)
The consequences of the 2013–16 Ebola Zaire virus disease epidemic in West Africa were grave. The economies, healthcare systems and communities of Guinea, Sierra Leone and Liberia were devastated by over 18 months of active Ebola virus transmission
Externí odkaz:
https://doaj.org/article/40c64edefea643de830eb816994756fa
Autor:
Muhammed O Afolabi, David Ishola, Daniela Manno, Babajide Keshinro, Viki Bockstal, Baimba Rogers, Kwabena Owusu-Kyei, Alimamy Serry-Bangura, Ibrahim Swaray, Brett Lowe, Dickens Kowuor, Frank Baiden, Thomas Mooney, Elizabeth Smout, Brian Köhn, Godfrey T Otieno, Morrison Jusu, Julie Foster, Mohamed Samai, Gibrilla Fadlu Deen, Heidi Larson, Shelley Lees, Neil Goldstein, Katherine E Gallagher, Auguste Gaddah, Dirk Heerwegh, Benoit Callendret, Kerstin Luhn, Cynthia Robinson, Brian Greenwood, Maarten Leyssen, Macaya Douoguih, Bailah Leigh, Deborah Watson-Jones, M Kargbo, E Bockarie, N L James, A Kabbah, A Kamara, K H Koroma, S O Langley, N William, R Kessebeh, T Mooney, L Conteh, E Smout, K Allieu, K Bangura, M S Bangura, M A Bangura, H Jalloh, A B Jalloh, I Kamara, M Kamara, A Konteh, S Koroma, C Marrah, M Sesay, M T Sesay, A T Deen, A Jalloh, R M Kaimbay, D Kain, E L Kamara, M P Kamara, O J Kamara, S L M Kamara, M Kanneh, A H Koroma, D Lahai, I S Mansaray, W S Marah, M J Massaquoi, A Nabie, N S Saidu, I Samai, J N Tengheh, A S Turay, A Fornah, F Sesay, A Sow, E Swaray, F Mansaray, T Ade-Cole, L M Bangura, M L Conteh, A M Koroma, M Koroma, A Sam, T Scott, T Sessie, J-H C Sunders, S I-S Turay, J Weekes, M Sheku, L Gibson, D Kowuor, I Ahamed, W Allieu, D U Kabba, F J Kamara, M S Kebbie, M Pessima, A Wurie, F Bah, A I Bangura, R A S Bangura, L Blango, S Boima, M Conteh, Y Conteh, M L Daramy, O Fofanah, E George, T F Hanson, M I Jalloh, M Kalawa, A M Kamara, F E Kamara, G M Kamara, H M Kamara, P B D Kamara, R T Kamara, R Kamara, D P Kanneh, I Komeh, M Kuyateh, F F Mansaray, M M Mansaray, A B Sillah, M A Tarawally, O S Turya, J B Yawmah, B Leigh, D Watson-Jones, B Greenwood, M H Samai, G F Deen, D Marke, T Sesay, P Piot, P Smith, J Edmunds, S Lees, H Larson, H Weiss, P Wilson, R Phillips, C Maxwell, D Ishola, M Afolabi, F Baiden, P Akoo, K Owusu-Kyei, D Tindanbil, H Bower, J Stuart, O M Bah, B T Rogers, A Serry-Bangura, I B Swaray, A Bangura, I J David, D G M Davies, J A Kallon, A B Kamara, I F Kamara, M M Kamara, F E Morovia, F B Suma, F Thompson, M Murray, O Kakay, F Suma, I Sesay, J Foster, D Manno, K Gallagher, S Cox, N Howard, M Cesay, P Torrani, S Sharma, E Snowden, T Banks, T Harber, J Brown, K Howard, N Melton, S Malcolm, S Welsh, R Eggo, M Jendrossek, C Pearson, K Offergeld, C Ferrault, M Van Alst, N Mahajan, M Van Looveren, S Van Ballaert, T De Cnodder, N Grobler, L Roza, T Liberi, L Armishaw, C Verkleij, T Henrick, A Banaszkiewicz, B Lowe, K Awuondo, H Hafezi, E Hancox, B Kohn, G O Tuda, G Bangura, M T Kroma, L Fofanah, A Pessima, M Rogers, O Sheriff, T W Ajala, J Fangawa, S Foday Jr, I S F Koroma, B Mansaray, H A Mansaray, K Sesay, M K Charles, P C Heroe, M Lamin Karbo, I S Yansaneh, S Gogo Egoeh, A Trye, M Amponsah, L Donelson, T Sylvester, V Owira, G Onyuka, L Nambuchi, A Oburu, D Apollo, L Vandi, N D Alghali, A Bah, I J Bangura, A C Cole, S Fofanah, H U Jalloh, K F N Jalloh, N Jalloh, H U Kabba, J N Kabba, M Kabba, J S Kamara, F Kanjie, A P Kanu, I Kargbo, G Kassa-Koroma, S B Koroma, A Sankoh, T Sankoh, O D Sesay, H Wilhem, C T Williams, I Bangura, Y Ben-Rogers, F J Jamboria, N Kamara, I Kanawah, A T Kargbo, I Swaray, L Amara, I Bundu, H B Jakema, K Kamara, M F Sheku, Q Adeleye, I Akhigbe, R Bakalemwa, N P Chami, L Altmann, B Kamara, K van Roey, P Conteh, M Samura, V Gandie, M Marrah, E Moinina, J Kalokoh, S Bosompem, T Hilton, M O Jusu, P Borboh, A S Brima, A F Y Caulker, A Kallon, B Koroma, R C Macauley, T M D Saquee, H I Williams, A R Bangura, J Fornah, B Idriss, M Sillah, W Mackay, B Aleghen, T Murray, J Edem-Hotah, T Fatorma, F Amara, S Bangura, E Bonnie, M Sannoh, A Donaldson, S Ndingi, D Nyaberi, M Pereira, A Rothwell, V Vy, L Nyallay, A Fombah, S Saidu, T P Dambo, P J Fakaba, M M E Fatorma, R H Freeman, C L Johnson, D B Kogba, A Lahai, W Vincent, N Yambasu, M Bangura, A Tengbeh, R Kabia, A M Nyakoi, M Callaghan, L Enria, S Lee
Publikováno v:
The Lancet Infectious Diseases. 22:110-122
Summary Background Children account for a substantial proportion of cases and deaths from Ebola virus disease. We aimed to assess the safety and immunogenicity of a two-dose heterologous vaccine regimen, comprising the adenovirus type 26 vector-based
Autor:
Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, Gaudensia Mutua, Sodiomon B. Sirima, Serge Eholie, Hannah Kibuuka, Christine Bétard, Laura Richert, Christine Lacabaratz, M. Juliana McElrath, Stephen C. De Rosa, Kristen W. Cohen, Georgi Shukarev, Michael Katwere, Cynthia Robinson, Auguste Gaddah, Dirk Heerwegh, Viki Bockstal, Kerstin Luhn, Maarten Leyssen, Rodolphe Thiébaut, Macaya Douoguih, on behalf of the EBL2002 Study group
Publikováno v:
PLoS Medicine
PLoS Medicine, Public Library of Science, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1 (2022)
PLoS Medicine, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1, p e1003865 (2022)
PLoS Medicine, Public Library of Science, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1 (2022)
PLoS Medicine, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1, p e1003865 (2022)
Background Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness and death in thousands of adults and children. The objective of this study was to assess safety, tolerability, and immunogenicity of the heterologous 2-dose
Autor:
Georgi Shukarev, Helen R Wagstaffe, Jeroen N Stoop, Viki Bockstal, Eleanor M. Riley, Kerstin Luhn, Matthew D. Snape, Andrew J. Pollard, Martin R. Goodier, Macaya Douoguih, Elizabeth A. Clutterbuck
Publikováno v:
The Journal of Infectious Diseases
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E M & Goodier, M R 2019, ' Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination ', The Journal of Infectious Diseases . https://doi.org/10.1093/infdis/jiz657
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E M & Goodier, M R 2019, ' Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination ', The Journal of Infectious Diseases . https://doi.org/10.1093/infdis/jiz657
Background Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dependent
Autor:
Hilary S. Whitworth, Pontiano Kaleebu, George PrayGod, Macaya Douoguih, Saidi Kapiga, Deborah Watson-Jones, Dickson Anumendem, Kerstin Luhn, Samuel E. Kalluvya, Cynthia Robinson, Georgi Shukarev, Daniela Manno, Viki Bockstal, Zacchaeus Anywaine, Heiner Grosskurth
Publikováno v:
The Journal of Infectious Diseases
Background Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccina
Autor:
Bart Spiessens, Ramon Roozendaal, Liesbeth Dekking, Maria Grazia Pau, Cynthia Robinson, Dominika N. Czapska-Casey, Yvonne Wollmann, Thierry Van Effelterre, Viki Bockstal, Eline Dekeyster, Roland Zahn, Jeroen N Stoop, Kerstin Luhn, Jan Serroyen, Luis D. Giavedoni, Jenny Hendriks, Sarah Janssen, Maarten Leyssen, Ben Van Baelen, Hanneke Schuitemaker, Ricardo Carrion, Daniel Splinter, An Vandebosch, Jerry Sadoff, Ariane Volkmann, Nadia Verbruggen, Macaya Douoguih, Laura Solforosi, Benoit Callendret
Publikováno v:
NPJ VACCINES
npj Vaccines
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-11 (2020)
npj Vaccines
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-11 (2020)
It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of a vaccine protective effect, by translating vaccine immun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a435e1265a441954725ed3930a761f9
http://hdl.handle.net/1887/3562934
http://hdl.handle.net/1887/3562934
Autor:
Marc Gurwith, Eric Evans, Frank Tomaka, Hanneke Schuitemaker, Denny Kim, Maarten Leyssen, Richard C. Condit, James S. Robertson, Dirk Heerwegh, Jerome Custers, Macaya Douoguih, Esther Heijnen, Roy van Heesbeen, Georgi Shukarev, Robert T. Chen, Emily R. Smith
Publikováno v:
Vaccine
Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express various antigens as a basis for preventive or therapeutic vaccine development. A replication incompetent adenoviral v